Deletion mutations conferring substrate spectrum extension in the class A β-lactamase

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 6265-6269

  Hwang, Junghyun ^a   Cho, Kwang Hwi ^c   Song, Han ^a   Yi, Hyojeong ^a   Kim, Heenam Stanley ^a,b  

^a Departments of Medicinea and Biosystems and Biotechnology   (South Korea)

^b Korea University   (South Korea)

^c Soongsil University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE PENA; CEFTAZIDIME; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BURKHOLDERIA THAILANDENSIS; CODON; DNA FLANKING REGION; GENE DELETION; GENE MUTATION; MICHAELIS MENTEN KINETICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; SEQUENCE ALIGNMENT; BURKHOLDERIA; ENZYMOLOGY; GENETICS;

BETA-LACTAMASES; BURKHOLDERIA; SEQUENCE DELETION;

EID: 84907262637     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02648-14     Document Type: Article

References (35)

1. Coates A, Hu Y, Bax R, Page C. 2002. The future challenges facing the development of new antimicrobial drugs. Nat. Rev. Drug Discov. 1:895-910. http://dx.doi.org/10.1038/nrd940.
2. Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI. 2011. Tackling antibiotic resistance. Nat. Rev. Microbiol. 9:894-896. http://dx.doi.org/10.1038/nrmicro2693.
3. Bush K, Fisher JF. 2011. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from Gram-negative bacteria. Annu. Rev. Microbiol. 65:455-478. http://dx.doi.org/10.1146/annurev-micro-090110-102911.
4. Pitout JD, Laupland KB. 2008. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8:159-166. http://dx.doi.org/10.1016/S1473-3099(08)70041-0.
5. Drawz SM, Bonomo RA. 2010. Three decades of beta-lactamase inhibitors. Clin. Microbiol. Rev. 23:160-201. http://dx.doi.org/10.1128/CMR.00037-09.
6. Elander RP. 2003. Industrial production of β-lactam antibiotics. Appl. Microbiol. Biotechnol. 61:385-392. http://dx.doi.org/10.1007/s00253-003-1274-y.
7. Yi H, Cho KH, Cho YS, Kim K, Nierman WC, Kim HS. 2012. Twelve positions in a beta-lactamase that can expand its substrate spectrum with a single amino acid substitution. PLoS One 7(5):e37585. http://dx.doi.org/10.1371/journal.pone.0037585.
8. Ho PL, Cheung TK, Yam WC, Yuen KY. 2002. Characterization of a laboratory-generated variant of BPS β-lactamase from Burkholderia pseudomallei that hydrolyses ceftazidime. J. Antimicrob. Chemother. 50: 723-726. http://dx.doi.org/10.1093/jac/dkf208.
9. Salverda ML, De Visser JA, Barlow M. 2010. Natural evolution of TEM-1 β-lactamase: experimental reconstruction and clinical relevance. FEMS Microbiol. Rev. 34:1015-1036. http://dx.doi.org/10.1111/j.1574-6976.2010.00222.x.
10. Abriata LA, Salverda ML, Tomatis PE. 2012. Sequence-function-stability relationships in proteins from datasets of functionally annotated variants: the case of TEM β-lactamases. FEBS Lett. 586:3330-3335. http://dx.doi.org/10.1016/j.febslet.2012.07.010.
11. Simm AM, Baldwin AJ, Busse K, Jones DD. 2007. Investigating protein structural plasticity by surveying the consequence of an amino acid deletion from TEM-1 β-lactamase. FEBS Lett. 581:3904-3908. http://dx.doi.org/10.1016/j.febslet.2007.07.018.
12. Brett PJ, DeShazer D, Woods DE. 1998. Note: Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species. Int. J. Syst. Bacteriol. 48:317-320. http://dx.doi.org/10.1099/00207713-48-1-317.
13. Kim HS, Schell M, Yu Y, Ulrich R, Sarria S, Nierman W, DeShazer D. 2005. Bacterial genome adaptation to niches: divergence of the potential virulence genes in three Burkholderia species of different survival strategies. BMC Genomics 6:174. http://dx.doi.org/10.1186/1471-2164-6-174.
14. Yi H, Kim K, Cho KH, Jung O, Kim HS. 2012. Substrate spectrum extension of PenA in Burkholderia thailandensis with a single amino acid deletion, Glu168del. Antimicrob. Agents Chemother. 56:4005-4008. http://dx.doi.org/10.1128/AAC.00598-12.
15. Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ. 2006. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat. Rev. Microbiol. 4:272-282. http://dx.doi.org/10.1038/nrmicro1385.
16. Cheng AC, Currie BJ. 2005. Melioidosis: epidemiology, pathophysiology, and management. Clin. Microbiol. Rev. 18:383-416. http://dx.doi.org/10.1128/CMR.18.2.383-416.2005.
17. Nierman W, DeShazer D, Kim H, Tettelin H, Nelson K, Feldblyum T, Ulrich R, Ronning C, Brinkac L, Daugherty S. 2004. Structural flexibility in the Burkholderia genome. Proc. Natl. Acad. Sci. U. S. A. 101:14246-14251. http://dx.doi.org/10.1073/pnas.0403306101.
18. Song H, Hwang J, Yi H, Ulrich RL, Yu Y, Nierman WC, Kim HS. 2010. The early stage of bacterial genome-reductive evolution in the host. PLoS Pathog. 6(5):e1000922. http://dx.doi.org/10.1371/journal.ppat.1000922.
19. Wuthiekanun V, Peacock SJ. 2006. Management of melioidosis. Expert Rev. Anti Infect. Ther. 4:445-455. http://dx.doi.org/10.1586/14787210.4.3.445.
20. Estes DM, Dow SW, Schweizer HP, Torres AG. 2010. Present and future therapeutic strategies for melioidosis and glanders. Expert Rev. Anti Infect. Ther. 8:325-338. http://dx.doi.org/10.1586/eri.10.4.
21. Banerjee S, Pieper U, Kapadia G, Pannell LK, Herzberg O. 1998. Role of the β-Loop in the activity, substrate specificity, and structure of class A β-lactamase. Biochemistry 37:3286-3296. http://dx.doi.org/10.1021/bi972127f.
22. Joyce LF, Downes J, Stockman K, Andrew JH. 1992. Comparison of five methods, including the PDM epsilometer test (E test), for antimicrobial susceptibility testing of Pseudomonas aeruginosa. J. Clin. Microbiol. 30: 2709-2713.
23. Keen NT, Tamaki S, Kobayashi D, Trollinger D. 1988. Improved broadhost-range plasmids for DNA cloning in Gram-negative bacteria. Gene 70:191-197. http://dx.doi.org/10.1016/0378-1119(88)90117-5.
24. Cavallo JD, Fabre R, Leblanc F, Nicolas-Chanoine MH, Thabaut A, Groupe d'Etude de la Résistance de Pseudomonas aeruginosa aux Bêtalactamines. 2000. Antibiotic susceptibility and mechanisms of β-lactam resistance in 1310 strains of Pseudomonas aeruginosa: a French multicentre study. J. Antimicrob. Chemother. 46:133-136. http://dx.doi.org/10.1093/jac/46.1.133.
25. Wang X, Minasov G, Shoichet BK. 2002. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J. Mol. Biol. 320:85-95. http://dx.doi.org/10.1016/S0022-2836(02)00400-X.
26. Tribuddharat C, Moore RA, Baker P, Woods DE. 2003. Burkholderia pseudomallei class A beta-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition. Antimicrob. Agents Chemother. 47:2082-2087. http://dx.doi.org/10.1128/AAC.47.7.2082-2087.2003.
27. Dixon M. 1953. The determination of enzyme inhibitor constants. Biochem. J. 55:170-171.
28. Papp-Wallace KM, Taracila MA, Gatta JA, Ohuchi N, Bonomo RA, Nukaga M. 2013. Insights into β-lactamases from Burkholderia species, two phylogenetically related yet distinct resistance determinants. J. Biol. Chem. 288:19090-19102. http://dx.doi.org/10.1074/jbc.M113.458315.
29. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, Duke RE, Luo R, Walker RC, Zhang W, Merz KM, Roberts B, Hayik S, Roitberg A, Seabra G, Swails J, Goetz AW, Kolossváry I, Wong KF, Paesani F, Vanicek J, Wolf RM, Liu J, Wu X, Brozell SR, Steinbrecher T, Gohlke H, Cai Q, Ye X, Wang J, Hsieh M-J, Cui G, Roe DR, Mathews DH, Seetin MG, Salomon-Ferrer R, Sagui C, Babin V, Luchko T, Gusarov S, Kovalenko A, Kollman PA. 2012. Amber 12. University of California, San Francisco, CA. http://ambermd.org/.
30. Jelsch C, Mourey L, Masson JM, Samama JP. 1993. Crystal structure of Escherichia coliTEM1beta-lactamase at 1.8Aresolution. Proteins 16:364-383. http://dx.doi.org/10.1002/prot.340160406.
31. Raquet X, Lamotte-Brasseur J, Fonz E, Goussard S, Courvalin P, Frere JM. 1994. TEM beta-lactamase mutants hydrolysing third-generation cephalosporins: a kinetic and molecular modelling analysis. J. Mol. Biol. 244:625-639. http://dx.doi.org/10.1006/jmbi.1994.1756.
32. Vakulenko SB, Toth M, Taibi P, Mobashery S, Lerner SA. 1995. Effects of Asp-179 mutations in TEMpUC19 beta-lactamase on susceptibility to beta-lactams. Antimicrob. Agents Chemother. 39:1878-1880. http://dx.doi.org/10.1128/AAC.39.8.1878.
33. Matagne A, Lamotte-Brasseur J, Frere JM. 1998. Catalytic properties of class A beta-lactamases: efficiency and diversity. Biochem. J. 330: 581-598.
34. Wong W-T, Chan K-C, So P-K, Yap H-K, Chung W-H, Leung Y-C, Wong K-Y, Zhao Y. 2011. Increased structural flexibility at the active site of a fluorophore-conjugated β-lactamase distinctively impacts its binding toward diverse cephalosporin antibiotics. J. Biol. Chem. 286:31771-31780. http://dx.doi.org/10.1074/jbc.M110.198895.
35. Ambler RP, Coulson AF, Frere JM, Ghuysen JM, Joris B, Forsman M, Levesque RC, Tiraby G, Waley SG. 1991. A standard numbering scheme for the class A beta-lactamases. Biochem. J. 276(Pt 1):269-270.